Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP859232.RA5fVa9TBG4_jPLZk3O7JgVL0mKX5kW00dPn-9A8eyDmM130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP859232.RA5fVa9TBG4_jPLZk3O7JgVL0mKX5kW00dPn-9A8eyDmM130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP859232.RA5fVa9TBG4_jPLZk3O7JgVL0mKX5kW00dPn-9A8eyDmM130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP859232.RA5fVa9TBG4_jPLZk3O7JgVL0mKX5kW00dPn-9A8eyDmM130_provenance.
- NP859232.RA5fVa9TBG4_jPLZk3O7JgVL0mKX5kW00dPn-9A8eyDmM130_assertion wasGeneratedBy ECO_0000203 NP859232.RA5fVa9TBG4_jPLZk3O7JgVL0mKX5kW00dPn-9A8eyDmM130_provenance.
- NP859232.RA5fVa9TBG4_jPLZk3O7JgVL0mKX5kW00dPn-9A8eyDmM130_assertion wasDerivedFrom befree-20140225 NP859232.RA5fVa9TBG4_jPLZk3O7JgVL0mKX5kW00dPn-9A8eyDmM130_provenance.
- NP859232.RA5fVa9TBG4_jPLZk3O7JgVL0mKX5kW00dPn-9A8eyDmM130_assertion SIO_000772 23427296 NP859232.RA5fVa9TBG4_jPLZk3O7JgVL0mKX5kW00dPn-9A8eyDmM130_provenance.
- NP859232.RA5fVa9TBG4_jPLZk3O7JgVL0mKX5kW00dPn-9A8eyDmM130_assertion evidence source_evidence_literature NP859232.RA5fVa9TBG4_jPLZk3O7JgVL0mKX5kW00dPn-9A8eyDmM130_provenance.
- NP859232.RA5fVa9TBG4_jPLZk3O7JgVL0mKX5kW00dPn-9A8eyDmM130_assertion description "[CD74 is a suitable target for ADCs in some solid tumor xenografts, with efficacy largely influenced by uniformity of CD74 expression and with SN-38 conjugates providing the best therapeutic responses; SN-38 conjugates were preferable in solid cancers, whereas doxorubicin ADC was better in lymphoma tested.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP859232.RA5fVa9TBG4_jPLZk3O7JgVL0mKX5kW00dPn-9A8eyDmM130_provenance.
- befree-20140225 importedOn "2014-02-25" NP859232.RA5fVa9TBG4_jPLZk3O7JgVL0mKX5kW00dPn-9A8eyDmM130_provenance.